Homozygous COQ7 mutation: a new cause of potentially treatable distal hereditary motor neuropathy.
Arnaud JacquierJulian TheurietFanny FontaineValentine MosbachNicolas LacosteShams RibaultValérie RissonJulien CarrasLaurent CoudertThomas SimonetPhilippe LatourTanya StojkovicJuliette PiardAnne CossonGaëtan LescaFrançoise BouhourStéphane AlloucheHélène PuccioAntoine PégatLaurent SchaefferPublished in: Brain : a journal of neurology (2022)
Distal hereditary motor neuropathy represents a group of motor inherited neuropathies leading to distal weakness. We report a family of two brothers and a sister affected by distal hereditary motor neuropathy in whom a homozygous variant c.3G > T (p.1Met? ) was identified in the COQ7 gene. This gene encodes a protein required for Coenzyme Q10 biosynthesis, a component of the respiratory chain in mitochondria. Mutations of COQ7 were previously associated with severe multi-organ disorders characterized by early childhood onset and developmental delay. Using patient blood sample and fibroblasts derived from a skin biopsy, we investigated the pathogenicity of the variant of unknown significance c.3G > T (p.1Met? ) in the COQ7 gene and the effect of Coenzyme Q10 supplementation in vitro. We showed that this variation leads to a severe decrease in COQ7 protein levels in the patient's fibroblasts, resulting in a decrease in Coenzyme Q10 production, and in the accumulation of 6-demethoxycoenzyme Q10, the COQ7 substrate. Interestingly, such accumulation was also found in the patient's plasma. Normal Coenzyme Q10 and 6-demethoxycoenzyme Q10 levels were restored in vitro by using the Coenzyme Q10 precursor 2,4-dihydroxybenzoic acid, thus bypassing COQ7 requirement. Coenzyme Q10 biosynthesis deficiency is known to impair mitochondrial respiratory chain. Seahorse experiments showed that the patient's cells mainly rely on glycolysis to maintain sufficient ATP production. Consistently, the replacement of glucose by galactose in the culture medium of these cells reduced their proliferation rate. Interestingly, normal proliferation was restored by Coenzyme Q10 supplementation in the culture medium, suggesting a therapeutic avenue for these patients. Altogether, we have identified the first example of recessive distal hereditary motor neuropathy caused by a homozygous variation in the COQ7 gene, which should thus be included in the gene panels used to diagnose peripheral inherited neuropathies. Furthermore, 6-demethoxycoenzyme Q10 accumulation in the blood can be used to confirm the pathogenic nature of the mutation. Finally, supplementation with Coenzyme Q10 or derivatives should be considered to prevent the progression of COQ7-related peripheral inherited neuropathy in diagnosed patients.
Keyphrases
- end stage renal disease
- copy number
- minimally invasive
- genome wide
- case report
- induced apoptosis
- newly diagnosed
- genome wide identification
- chronic kidney disease
- signaling pathway
- prognostic factors
- oxidative stress
- blood pressure
- patient reported outcomes
- dna methylation
- binding protein
- gene expression
- transcription factor
- type diabetes
- biofilm formation
- genome wide analysis
- cell proliferation
- staphylococcus aureus
- escherichia coli
- weight loss
- intellectual disability
- endoplasmic reticulum stress
- soft tissue
- pi k akt
- smoking cessation
- myasthenia gravis
- patient reported